BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cole TO, Robinson D, Kelley-Freeman A, Gandhi D, Greenblatt AD, Weintraub E, Belcher AM. Patient Satisfaction With Medications for Opioid Use Disorder Treatment via Telemedicine: Brief Literature Review and Development of a New Assessment. Front Public Health 2020;8:557275. [PMID: 33553083 DOI: 10.3389/fpubh.2020.557275] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Teck JTW, Zlatkute G, Perez A, Dritschel H, Ghosh A, Potenza MN, Ambekar A, Ekhtiari H, Stein D, Khazaal Y, Arunogiri S, Torrens M, Ferri M, Galea-singer S, Baldacchino A. Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory. The Lancet Psychiatry 2023;10:50-64. [DOI: 10.1016/s2215-0366(22)00374-1] [Reference Citation Analysis]
2 Saunders EC, Satcher MF, Monico LB, McDonald RD, Springer SA, Farabee D, Gryczynski J, Nyaku A, Reeves D, Kunkel LE, Schultheis AM, Schwartz RP, Lee JD, Marsch LA, Waddell EN. The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study. Health Justice 2022;10:35. [PMID: 36529829 DOI: 10.1186/s40352-022-00199-1] [Reference Citation Analysis]
3 Harrington C, Bailey A, Delorme E, Hano S, Evans EA. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19. Subst Use Misuse 2023;58:266-74. [PMID: 36510800 DOI: 10.1080/10826084.2022.2155480] [Reference Citation Analysis]
4 Alexander K, Smith JM, Gerolamo A, Bernhardt J. The impact of nursing on health outcomes of people receiving medication for opioid use disorder: An integrative review. J of Nursing Scholarship 2022. [DOI: 10.1111/jnu.12858] [Reference Citation Analysis]
5 Ait-Daoud Tiouririne N, Coley J, Kalelioglu T, Schorling K. Feasibility Pilot Study of an Opioid Helpline for Individuals at High Risk for Opioid Use Disorder. J Addict Med 2022. [PMID: 36161978 DOI: 10.1097/ADM.0000000000001086] [Reference Citation Analysis]
6 Poulsen MN, Santoro W, Scotti R, Henderson C, Ruddy M, Colistra A. Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19. J Addict Med 2022. [PMID: 36129690 DOI: 10.1097/ADM.0000000000001079] [Reference Citation Analysis]
7 Mahmoud H, Naal H, Whaibeh E, Smith A. Telehealth-Based Delivery of Medication-Assisted Treatment for Opioid Use Disorder: a Critical Review of Recent Developments. Curr Psychiatry Rep 2022. [PMID: 35895282 DOI: 10.1007/s11920-022-01346-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sousa JL, Raja P, Huskamp HA, Mehrotra A, Busch AB, Barnett ML, Uscher-Pines L. Perspectives of Patients Receiving Telemedicine Services for Opioid Use Disorder Treatment: A Qualitative Analysis of User Experiences. J Addict Med 2022. [PMID: 35861337 DOI: 10.1097/ADM.0000000000001006] [Reference Citation Analysis]
9 Racha S, Buresh M, Fingerhood M. Pharmacotherapy of Opioid Use Disorder—Update and Current Challenges. Psychiatric Clinics of North America 2022. [DOI: 10.1016/j.psc.2022.04.001] [Reference Citation Analysis]
10 Lockard R, Priest KC, Gregg J, Buchheit BM. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. Substance Abuse 2022;43:1150-7. [DOI: 10.1080/08897077.2022.2060447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Swann WL, Schreiber TL, Kim SY, Mcneely H, Hong JH. Perceived impact of COVID-19 on prevention, treatment, harm reduction, and recovery services for opioid use disorder: National survey of local health departments. Substance Abuse 2022;43:993-8. [DOI: 10.1080/08897077.2022.2060429] [Reference Citation Analysis]
12 Hageman TM, Palmer J, Mullick P, Lee H. A Buprenorphine Program Evaluation Before and During the COVID-19 Pandemic. J Nurse Pract 2022. [PMID: 35013677 DOI: 10.1016/j.nurpra.2021.12.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shapira B, Neumark Y. Substance Use Disorder Treatment in the Age of COVID-19: Challenges, Responses, and Lessons for the Future. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-67928-6_17-1] [Reference Citation Analysis]
14 Shapira B, Neumark Y. Substance Use Disorder Treatment in the Age of COVID-19: Challenges, Responses, and Lessons for the Future. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-92392-1_17] [Reference Citation Analysis]
15 Gregory HM, Hill VM, Parker RW. Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions. Cureus 2021. [DOI: 10.7759/cureus.19870] [Reference Citation Analysis]
16 Philippe TJ, Sikder N, Jackson A, Koblanski ME, Liow E, Pilarinos A, Vasarhelyi K. Digital Health Interventions for Delivery of Mental Health Care: Systematic and Comprehensive Meta-Review (Preprint). JMIR Mental Health. [DOI: 10.2196/35159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Philippe TJ, Sikder N, Jackson A, Koblanski ME, Liow E, Pilarinos A, Vasarhelyi K. Digital Health Interventions for Delivery of Mental Health Care: Systematic and Comprehensive Meta-Review (Preprint).. [DOI: 10.2196/preprints.35159] [Reference Citation Analysis]
18 Melamed OC, deRuiter WK, Buckley L, Selby P. Coronavirus Disease 2019 and the Impact on Substance Use Disorder Treatments. Psychiatric Clinics of North America 2021. [DOI: 10.1016/j.psc.2021.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Guillen AG, Reddy M, Saadat S, Chakravarthy B. Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review. Telemed J E Health 2021. [PMID: 34714172 DOI: 10.1089/tmj.2021.0308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]